MOUNTAIN VIEW, Calif., Jan. 30, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. today announced that it will hold a conference call at 8:30 a.m. Eastern Time tomorrow, Monday, January 31, to discuss partnering plans for LEVADEX(TM). LEVADEX is MAP Pharmaceuticals' novel, orally inhaled, migraine therapy that has completed Phase 3 clinical development for the treatment of acute migraine.
Conference Call / Webcast Details
To participate in the live call on Monday, January 31, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time), please dial 877-280-7473 for domestic callers and 707-287-9370 for international callers. Individuals interested in listening to the live call via webcast may do so by visiting the Investor Relations page of http://www.mappharma.com/.
About MAP Pharmaceuticals
MAP Pharmaceuticals is an emerging biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX(TM) orally inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of its Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.
Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com/.
CONTACTS: Nicole Foderaro WCG (415) 215-5643 nfoderaro@wcgworld.com
MAP Pharmaceuticals, Inc.
CONTACT: Nicole Foderaro, WCG, +1-415-215-5643, nfoderaro@wcgworld.com
Web Site: http://www.mappharma.com/
